{"disease":{"id":"macular-degeneration","name":"macular degeneration"},"drugs":{"marketed":[{"drug_id":"aflibercept","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vegf Trap","generic_name":"AFLIBERCEPT","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"Vascular Endothelial Growth Factor Inhibitor","quality_score":55,"revenue":"9800","mechanism":""},{"drug_id":"faricimab","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vabysmo","generic_name":"FARICIMAB","company_name":"Roche","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":62,"revenue":"5500","mechanism":"Vabysmo works by blocking the activity of a protein called vascular endothelial growth factor A."},{"drug_id":"avacincaptad-pegol-sodium","indication_name":"Geographic atrophy secondary to age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AVACINCAPTAD PEGOL SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitors","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"anecortave","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retaane","generic_name":"anecortave","company_name":"","drug_phase":"marketed","molecular_target":"Plasminogen activator inhibitor 1","drug_class":"anecortave","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"visudyne","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Visudyne","company_name":"Bayer","drug_phase":"discontinued","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"eylea","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Eylea","company_name":"Texas Retina Associates","drug_phase":"marketed","molecular_target":"Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"faricimab-svoa","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"VABYSMO","generic_name":"FARICIMAB-SVOA","company_name":"GENENTECH INC","drug_phase":"marketed","molecular_target":"Angiopoietin-2, Vascular endothelial growth factor A","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"lucentis","indication_name":"Age related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lucentis","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lucentis","company_name":"Santen Inc.","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lutein","indication_name":"Age related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xanthophyll","generic_name":"LUTEIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Vitamin C [EPC]","quality_score":31,"revenue":null,"mechanism":""},{"drug_id":"avacincaptad-pegol","indication_name":"Geographic atrophy secondary to age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Izervay","generic_name":"AVACINCAPTAD PEGOL","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Izervay works by binding to and inhibiting the activity of Complement C5, a protein involved in the immune response."},{"drug_id":"pegaptanib","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Macugen","generic_name":"pegaptanib","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"brolucizumab","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Beovu","generic_name":"BROLUCIZUMAB","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":75,"revenue":null,"mechanism":"Beovu works by binding to vascular endothelial growth factor A (VEGF-A), preventing its interaction with its receptor and reducing vascular permeability and inflammation."},{"drug_id":"eye001","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Macugen","generic_name":"EYE001","company_name":"Valeant Pharms Llc","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"beovu","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Beovu","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"macugen","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Macugen","company_name":"Greater Houston Retina Research","drug_phase":"discontinued","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"avacincaptad","indication_name":"Geographic atrophy secondary to age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avacincaptad","company_name":"Aviceda Therapeutics, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ranibizumab-nuna","indication_name":"Age related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ranibizumab-eqrn","indication_name":"Neovascular (Wet) Age-Related Macular Degeneration (AMD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CIMERLI","generic_name":"RANIBIZUMAB-EQRN","company_name":"SANDOZ INC","drug_phase":"marketed","molecular_target":"","drug_class":"Vascular Endothelial Growth Factor Inhibitor [EPC]","quality_score":18,"revenue":null,"mechanism":""},{"drug_id":"ranibizumab-nuna","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BYOOVIZ","generic_name":"RANIBIZUMAB-NUNA","company_name":"SAMSUNG BIOEPIS CO LTD","drug_phase":"marketed","molecular_target":"Vascular endothelial growth factor A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"verteporfin","indication_name":"Exudative age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Visudyne","generic_name":"VERTEPORFIN","company_name":"Bausch Lomb Ireland","drug_phase":"marketed","molecular_target":"","drug_class":"Photoenhancer [EPC]","quality_score":10,"revenue":null,"mechanism":"Visudyne selectively binds to neovascular tissue, which is then activated by light to induce a phototoxic reaction."}],"pipeline":[],"offLabel":[],"totalMarketed":21,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05146687","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)","phase":"","overall_status":"COMPLETED","enrollment_count":369600,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05110209","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)","phase":"","overall_status":"COMPLETED","enrollment_count":331541,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03752840","title":"Village-Integrated Eye Worker Trial II","phase":"NA","overall_status":"RECRUITING","enrollment_count":60200,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT07308639","title":"DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05835115","title":"Development and Validation of a Deep Learning-based Myopia and Myopic Maculopathy Detection and Prediction System","phase":"","overall_status":"COMPLETED","enrollment_count":30526,"lead_sponsor_name":"Shanghai Eye Disease Prevention and Treatment Center","has_results":false},{"nct_id":"NCT05690880","title":"ForeseeHome NRich Registry","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Notal Vision Inc.","has_results":false},{"nct_id":"NCT05066685","title":"Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program","phase":"","overall_status":"COMPLETED","enrollment_count":18457,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03278587","title":"Village-Integrated Eye Worker Trial II - Pilot","phase":"NA","overall_status":"COMPLETED","enrollment_count":16075,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT07497815","title":"Artificial Intelligence-assisted Diagnosis in Ophthalmology","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Marisse Masis-Solano","has_results":false},{"nct_id":"NCT04187157","title":"Association Between Light Spectrum and Survival After Cataract Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":10192,"lead_sponsor_name":"University of Pittsburgh","has_results":false},{"nct_id":"NCT06203106","title":"NYSCF Scientific Discovery Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT05037396","title":"Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab","phase":"","overall_status":"COMPLETED","enrollment_count":9457,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05082415","title":"Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)","phase":"","overall_status":"COMPLETED","enrollment_count":9456,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05111743","title":"Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)","phase":"","overall_status":"COMPLETED","enrollment_count":9261,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05476926","title":"A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04847895","title":"Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications","phase":"","overall_status":"COMPLETED","enrollment_count":5500,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03128463","title":"Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Xun Xu","has_results":false},{"nct_id":"NCT07069647","title":"Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degeneration in Family Medicine and Geriatric Medicine Outpatient Clinics","phase":"NA","overall_status":"RECRUITING","enrollment_count":4300,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT01756248","title":"EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":3872,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT00001310","title":"Tissue Studies of Human Eye Diseases","phase":"","overall_status":"TERMINATED","enrollment_count":3833,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT01783925","title":"Eylea Post Marketing Surveillance(PMS)","phase":"","overall_status":"COMPLETED","enrollment_count":3206,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04985487","title":"Regulatory Post-Marketing Surveillance Study for Brolucizumab","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06929143","title":"A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT06943599","title":"Strategies for Improving Linkage-to-Care After Eye Disease Screening","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT00342251","title":"Investigating Age-Related Macular Degeneration","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT04935411","title":"Russian Registry of Patients With nAMD","phase":"","overall_status":"TERMINATED","enrollment_count":2665,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06583109","title":"Prediction Model of Treatment Efficacy for Age-related Macular Degeneration Based on Multi-source Imaging Modalities","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2600,"lead_sponsor_name":"Beijing Hospital","has_results":false},{"nct_id":"NCT06075147","title":"The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03278262","title":"The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting","phase":"","overall_status":"COMPLETED","enrollment_count":2312,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02540369","title":"To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.","phase":"","overall_status":"COMPLETED","enrollment_count":2150,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06021366","title":"Treatment Patterns With Brolucizumab in Germany - a Retrospective Cohort Study Based on Longitudinal Prescription Data: REALIZE Study","phase":"","overall_status":"COMPLETED","enrollment_count":2089,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06184360","title":"Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)","phase":"","overall_status":"COMPLETED","enrollment_count":2079,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07249307","title":"High-throughput Large-model-based AI-assisted Diagnosis Using OCT","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT00001733","title":"Screening for Studies on Retinovascular Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT05735730","title":"Can the Risk for AMD be Modulated?","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1800,"lead_sponsor_name":"Association for Innovation and Biomedical Research on Light and Image","has_results":false},{"nct_id":"NCT02307682","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1775,"lead_sponsor_name":"Alcon Research","has_results":true},{"nct_id":"NCT03939767","title":"Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease","phase":"","overall_status":"COMPLETED","enrollment_count":1563,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06213896","title":"Detecting Eye Diseases Via Hybrid Deep Learning Algorithms From Fundus Images","phase":"","overall_status":"COMPLETED","enrollment_count":1528,"lead_sponsor_name":"Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi","has_results":false},{"nct_id":"NCT06495203","title":"A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO","phase":"","overall_status":"COMPLETED","enrollment_count":1350,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04270604","title":"Biological Sample Collection for Research and Biobanking","phase":"","overall_status":"TERMINATED","enrollment_count":1279,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT04620876","title":"Bimodal and Coaxial High Resolution Ophtalmic Imaging","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","has_results":false},{"nct_id":"NCT03577899","title":"Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1157,"lead_sponsor_name":"Chengdu Kanghong Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT03630952","title":"Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1157,"lead_sponsor_name":"Chengdu Kanghong Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT06491914","title":"A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1118,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT07084883","title":"Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration","phase":"","overall_status":"RECRUITING","enrollment_count":1076,"lead_sponsor_name":"iHealthScreen Inc","has_results":false},{"nct_id":"NCT01986907","title":"Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1049,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02434328","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1048,"lead_sponsor_name":"Alcon Research","has_results":true},{"nct_id":"NCT04777201","title":"A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1036,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04423718","title":"Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1011,"lead_sponsor_name":"Bayer","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}